Polaris Genomics

Cover Block

Attribute	Value
Name	Polaris Genomics
Tagline	Mental health biomarker platform using AI-genomics from blood samples
Headquarters	Gaithersburg, Maryland
Founded	2017
Stage	Seed
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founders	Charles Cathlin, Tshaka Cunningham
Funding Label	Seed
Total Disclosed	~$3.4M

Links

• Website: https://polarisgenomics.com
• LinkedIn: https://www.linkedin.com/company/polarisgenomics

Executive Summary

Polaris Genomics is building a biomarker discovery platform for mental health, a bet that the field of psychiatry will shift from subjective assessment toward objective, biology-based diagnostics and therapeutic development. The company's ADAPT platform uses a targeted gene panel and machine learning to identify molecular signatures for conditions like PTSD, depression, and anxiety from blood samples [Polaris Genomics]. This thesis is backed by a founding narrative rooted in personal experience, with co-founder and CEO Charles Cathlin's motivation stemming from his time stationed at Ground Zero after 9/11 [Illumina]. The scientific leadership, including Chief Scientific Officer Tshaka Cunningham, a molecular biology PhD from Rockefeller University, provides the technical foundation [Polaris Genomics].

To date, the company has secured approximately $3.4 million in seed-stage capital from a notable syndicate that includes Viking Global Investors, Wing Venture Capital, and Sanford Health, alongside non-dilutive support from programs like the Illumina Accelerator and JLABS [Crunchbase, TEDCO]. The business model is B2B, targeting biotech and pharmaceutical companies as initial customers for its patented PTSD risk assay, positioning itself as a research tool rather than a direct-to-consumer diagnostic. Over the next 12-18 months, the critical watchpoints will be the validation of its biomarker signatures through published research, the announcement of its first commercial partnerships with named pharmaceutical entities, and its ability to translate academic and accelerator credibility into a repeatable commercial motion.

Data Accuracy: YELLOW -- Key company claims are self-reported; funding details are corroborated by multiple databases but lack independent press verification.

How the Company Got Here

Polaris Genomics was founded in 2017 as a veteran-owned biotech startup, with its mission rooted in a founder's direct experience at Ground Zero after the 9/11 attacks [Illumina]. The company is headquartered in Gaithersburg, Maryland, and positions itself as a precision mental health company focused on integrating genomics and AI to discover biomarkers for conditions like PTSD and depression [Polaris Genomics].

Key operational milestones include participation in the Illumina Accelerator program, which provided early access to sequencing technology and support [Illumina]. The company also secured a place in the Johnson & Johnson Innovation JLABS network in 2022, an award that included non-dilutive funding and mentorship [Polaris Genomics]. In 2023, Polaris Genomics received a $500,000 investment from TEDCO's SSBCI program to support its biomarker discovery platform [TEDCO, August 2023].

Data Accuracy: YELLOW -- Company website and press releases provide the narrative, with some milestones corroborated by third-party sources like TEDCO and Illumina.

Product and Technology

Polaris Genomics positions its core offering as the ADAPT Neuropsychiatric Biomarker Discovery Platform. The company describes this as a targeted gene panel analyzed via next-generation sequencing and machine learning to identify biomarker signatures from blood samples for conditions including PTSD, depression, anxiety, ADHD, traumatic brain injury, and substance use disorder [Polaris Genomics].

The platform's initial commercial wedge is a patented PTSD risk assay [Polaris Genomics]. This assay is sold to biotech and pharmaceutical researchers, R&D services, and developers of mental health diagnostics and therapeutics [Polaris Genomics]. The company claims its proprietary panel of neuropsychiatric biomarkers provides insights that whole transcriptome methods cannot [Polaris Genomics].

Technology partnerships form a visible part of the product narrative. Polaris Genomics has collaborated with the Illumina Accelerator, scientists from Mount Sinai, and researchers from the Max Planck Institute of Psychiatry [Polaris Genomics, Illumina].

Data Accuracy: YELLOW -- Product claims sourced solely from company materials; partnerships with named institutions provide partial corroboration.

Market Research and Opportunity

The push for objective biology in mental health diagnostics is creating a new commercial frontier for biomarker discovery. The broader global mental health market was valued at $383.3 billion in 2020 and is projected to reach $537.9 billion by 2030 [Allied Market Research, 2021]. The global market for companion diagnostics was estimated at $5.6 billion in 2022 and is projected to reach $13.6 billion by 2030 [Grand View Research, 2023].

Metric	Value
Global Mental Health Market 2020	$383.3B
Projected Mental Health Market 2030	$537.9B
Companion Diagnostics Market 2022	$5.6B
Projected Companion Dx Market 2030	$13.6B

Data Accuracy: YELLOW -- Market sizing relies on third-party analyst reports for analogous sectors; specific TAM for neuropsychiatric biomarkers is not publicly defined.

Competitive Landscape

Polaris Genomics operates in a nascent but increasingly crowded segment. The competitive map is fragmented across distinct business models and scientific approaches.

• Incumbent diagnostic giants. Companies like Genomic Health (now part of Exact Sciences) and Guardant Health have validated the liquid biopsy model in oncology, demonstrating the commercial viability of blood-based genomic tests.
• Direct-to-consumer genomics. 23andMe has built a massive consumer genetics database and has research programs in areas like depression and PTSD.
• Emerging research tools and AI platforms. A newer cohort of startups is applying multi-omics and machine learning to brain health.

Where Polaris has a potential edge today is in its early academic and institutional partnerships. Collaborations with the Illumina Accelerator, Mount Sinai, and the Max Planck Institute [Polaris Genomics] provide scientific credibility and access to specialized research cohorts.

Data Accuracy: YELLOW -- Competitive positioning is inferred from company claims and known market players.

Opportunity

If Polaris Genomics can translate its foundational research into a clinically validated diagnostic, it would capture a first-mover position in a market that has, for decades, lacked objective biological measures for mental health. The company’s core thesis addresses a critical gap in psychiatry [Polaris Genomics]. Its initial focus on a patented PTSD risk assay provides a specific, defensible wedge into the research market [Polaris Genomics].

Data Accuracy: YELLOW -- Core opportunity thesis is drawn from company statements and partner affiliations.

Sources

1. [Allied Market Research, 2021] Global Mental Health Market Report | https://www.alliedmarketresearch.com/mental-health-market-A12754
2. [Crunchbase] Polaris Genomics - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/polaris-genomics-830d
3. [EisnerAmper] How Health Care Advances for Veterans | https://www.eisneramper.com/insights/health-care/health-care-advances-veterans-podcast-0322/
4. [FDA, 2022] FDA Guidance on Biomarker Endpoints | https://www.fda.gov/regulatory-information/search-fda-guidance-documents
5. [Grand View Research, 2023] Companion Diagnostics Market Size Report | https://www.grandviewresearch.com/industry-analysis/companion-diagnostics-market
6. [Illumina] Polaris Genomics seeks to reveal invisible wounds | https://www.illumina.com/company/news-center/feature-articles/polaris-genomics-seeks-to-reveal-invisible-wounds-.html
7. [Polaris Genomics] About Us - Polaris Genomics | https://polarisgenomics.com/about-us/
8. [Polaris Genomics] From Ground Zero to Genomics: Charles Cathlin's Story | https://polarisgenomics.com/from-ground-zero-to-genomics-charles-cathlins-story/
9. [Polaris Genomics] Genomic-Led Health Meets People Where They Are, an Illumina Interview | https://polarisgenomics.com/genomic-led-health-meets-people-where-they-are-an-illumina-interview/
10. [Polaris Genomics] Home - Polaris Genomics | https://polarisgenomics.com/
11. [Polaris Genomics] Invest - Polaris Genomics | https://polarisgenomics.com/invest/
12. [Polaris Genomics] Our Milestones & Mission Move Us Forward | https://polarisgenomics.com/our-milestones-mission-move-us-forward/
13. [Polaris Genomics] Partnerships - Polaris Genomics | https://polarisgenomics.com/partnerships/
14. [Polaris Genomics] Polaris Genomics Advances Mental Health Biomarker Discovery | https://polarisgenomics.com/polaris-genomics-advances-mental-health-biomarker-discovery/
15. [Polaris Genomics] Redefining how mental health is understood and treated | https://polarisgenomics.com/redefining-how-mental-health-is-understood-and-treated/
16. [Polaris Genomics] Strengthening Our Scientific Team: Meet Nikolaos Daskalakis | https://polarisgenomics.com/strengthening-our-scientific-team/
17. [TEDCO, August 2023] TEDCO Announces SSBCI Investment in Polaris Genomics | https://www.tedcomd.com/news-events/press-releases/2023/tedco-announces-ssbci-investment-polaris-genomics
18. [World Health Organization, 2022] Mental health at work | https://www.who.int/news-room/fact-sheets/detail/mental-health-at-work